Dr. Kathryn P. Gray Joins Frontier Science Foundation

Dr. Kathryn P. Gray joined Frontier Science Foundation as Director of Biostatistics and Boston Office Director on March 1, 2019. Dr. Gray has been working in collaborative cancer clinical research, with the focus on gynecologic, breast, renal and prostate cancers, since 2010. She enjoys collaborating with investigators from multiple disciplines on clinical trial and translational studies with the goal of developing personalized cancer treatments.

Dr. Kathryn P. Gray

Dr. Gray has been the primary statistician for Dana Farber Cancer Institute’s (DFCI) Gynecologic Oncology Program providing statistical support and guidance for mostly phase I-II clinical trials that test new treatments for gynecologic cancer, including those targeting DNA repair, immunotherapy, antibody drug conjugates, and anti-angiogenesis agents, as well as trials studying strategies to overcome drug resistance. At DFCI, she has also worked with the Genitourinary (GU) cancer program, where she served as a senior statistician and provided statistical support for clinical trials and collaborated with investigators on many correlative/biomarker studies.

She is a member of the National Cancer Institute’s Gynecologic Cancers Steering Committee (GCSC). This committee reviews and prioritizes concepts for new phase II/III trials, and engages in strategic planning for directions for NCI-funded trials in gynecologic cancers. She is also the senior statistician with the International Breast Cancer Study Group (IBCSG), and has worked on a number of breast (phase II/III) cancer trials. She serves on the three-member translational research committee for IBCSG, which facilitates and provides guidance for research design, statistical considerations, and review of research proposals for projects using biological materials from IBCSG specimen banks. She has also collaborated on multiple translation research projects that investigate the prognostic and/or predicative associations between biomarkers or co-morbidities and disease outcomes, providing statistical design and analysis for such projects.

Prior to working at DFCI, Dr. Gray worked with the AIDS Clinical Trials Group (ACTG) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) group.

We welcome Dr. Kathryn Gray to Frontier Science!